Mexico's "first centre of excellence":
This article was originally published in Clinica
Executive Summary
Mexico has officially inaugurated the lysosomal storage disorders unit of the General Gaudencio Gonzalez Garza hospital, declaring it as the first in a series of centres of excellence that are to be established under the national social security institute IMSS. The hospital, located in Mexico's federal district, is the country's only centre specialising in lysosomal storage disorders and capable of diagnosing conditions such as Gaucher's, Fabry's and Pompe's diseases. These chronic-degenerative conditions are associated with high mortality and morbidity rates in Mexico, due to their late or missed diagnosis, claims the hospital. Although they are not curable, the advent of enzyme-replacement therapy, combined with quality diagnostic and treatment monitoring services, is said to be significantly improving their management. The centre began to operate in mid-2005.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.